engleski

Bypassing Major Venous Occlusion and Duodenal Lesions in Rats, and Therapy with the Stable Gastric Pentadecapeptide BPC 157, L‐NAME and L‐ arginine

Background Up to now, application of, prototype cytoprotective agent BPC 157 induced bypassing of occlusion, in rats underwent vessels occlusions, through rapid collaterals presentation. Aims To show that duodenal lesions induced by major venous occlusion can be attenuated by BPC 157, prototype cytoprotective agent, regardless NO system involvement. Methods In rats underwent superior anterior pancreaticoduodenal vein (SPDAV)-ligation, medication was bath at the ligated SAPDV (BPC 157 10 ug, 10 ng/kg/1ml bath/rat ; L-NAME 5 mg/kg/1ml bath/rat ; L-arginine 100 mg/kg/1ml bath/rat, alone and/or together ; or BPC 157 10 ug/kg instilled into rat stomach, at 1 min ligation-time. Results Unlike severe course in controls, after BPC 157 application, rats commonly exhibited strong attenuation of mucosal lesion and serosal congestion, improved vessels presentation, much more interconnections, branching raised more than 60% from the initial value ; inferior anterior pancreaticoduodenal vein (IAPDV) and superior mesenteric vein (SMV) were both non congested. Interestingly, while at 5 min and 30 min period alone L-NAME and L-arginine decreased mucosal and serosal duodenal lesions, their effect was worsening at 24 h period, no effect on the vessels collaterals and branching. Together, L-NAME+L- arginine antagonized each other response at any point, and thus, NO-related effect. With BPC 157 all SAPDV-ligated rats receiving L-NAME and/or L- arginine appear like rats treated with BPC 157 alone. Conclusions BPC 157, rapidly bypassing occlusion, rescued original duodenal flow through IAPDV to SMV flow, NO-system related effect.

BPC 157 ; duodenal lesion ; vessel occlusion

nije evidentirano